[go: up one dir, main page]

BR0004534A - Composto, composição farmacêutica, agente contendo um composto, e uso de um composto. - Google Patents

Composto, composição farmacêutica, agente contendo um composto, e uso de um composto.

Info

Publication number
BR0004534A
BR0004534A BR0004534-9A BR0004534A BR0004534A BR 0004534 A BR0004534 A BR 0004534A BR 0004534 A BR0004534 A BR 0004534A BR 0004534 A BR0004534 A BR 0004534A
Authority
BR
Brazil
Prior art keywords
group
compound
optionally substituted
pyrrole ring
pharmaceutical composition
Prior art date
Application number
BR0004534-9A
Other languages
English (en)
Inventor
Takaichi Shimozato
Nobuyuki Ohkawa
Tomio Kimura
Kazumasa Aoki
Shigeru Ushiyama
Akira Nakao
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BR0004534A publication Critical patent/BR0004534A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, AGENTE CONTENDO UM COMPOSTO, E, USO DE UM COMPOSTO" Compostos de fórmula (I): [em que: A é um anel pirrol; R^ 1^ é um grupo arila ou heteroarila opcionalmente substituído; R^ 2^ representa um grupo heteroarila contendo nitrogênio opcionalmente substituído; R^ 3^ representa um grupo da fórmula -X-R^ 4^, em que X é uma ligação simples ou um grupo alquileno, alquenileno ou alquinileno opcionalmente substituído, e R^ 4^ é um grupo cicloalquila substituído, um grupo arila substituído, um grupo heterociclila substituído, um grupo heterociclila contendo nitrogênio opcionalmente substituído, um grupo heterarila substituído, um grupo heterarila contendo nitrogênio opcionalmente substituído, ou -NR^ a^R^ b^, em que cada um de R^ a^ e R^ b^ é um átomo de hidrogênio ou um grupo alquila, alquenila, alquinila, aralquila ou alquilsulfonila; DESDE QUE os referidos substituintes R^ 1^ e R^ 3^ sejam ligados aos dois átomos do referido anel pirrol que são adjacentes ao átomo do anel pirrol ao qual o referido substituinte R^ 2^ está ligado] apresentam excelente atividade inibidora contra a produção de citosinas inflamatórias.
BR0004534-9A 1999-07-21 2000-07-21 Composto, composição farmacêutica, agente contendo um composto, e uso de um composto. BR0004534A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20549199 1999-07-21
JP36967899 1999-12-27

Publications (1)

Publication Number Publication Date
BR0004534A true BR0004534A (pt) 2001-02-28

Family

ID=26515088

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0004534-9A BR0004534A (pt) 1999-07-21 2000-07-21 Composto, composição farmacêutica, agente contendo um composto, e uso de um composto.

Country Status (22)

Country Link
EP (2) EP1243589A1 (pt)
KR (2) KR100776958B1 (pt)
CN (1) CN1294129C (pt)
AR (1) AR024904A1 (pt)
AT (1) ATE264319T1 (pt)
AU (1) AU773453B2 (pt)
BR (1) BR0004534A (pt)
CA (1) CA2314373A1 (pt)
DE (1) DE60009804T2 (pt)
DK (1) DK1070711T3 (pt)
ES (1) ES2216826T3 (pt)
HK (1) HK1047587A1 (pt)
HU (1) HUP0002846A2 (pt)
ID (1) ID26611A (pt)
IL (1) IL137365A0 (pt)
MX (1) MXPA00007199A (pt)
NO (1) NO20003734L (pt)
NZ (1) NZ505924A (pt)
PL (1) PL341620A1 (pt)
PT (1) PT1070711E (pt)
TR (1) TR200002120A2 (pt)
TW (1) TWI259834B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
EP1352906A4 (en) * 2001-01-18 2004-06-16 Sankyo Co COMPOSITIONS FOR PREVENTION OR TREATMENT OF LIVER DISEASES
EP1361225B1 (en) * 2001-01-22 2007-11-07 Sankyo Company, Limited Compounds substituted with bicyclic amino groups
WO2002057255A1 (en) * 2001-01-22 2002-07-25 Sankyo Company, Limited 4- or 5-substituted pyrrole derivatives
EG23054A (en) * 2001-01-22 2004-02-29 Sankyo Co Pyrrole derivatives their preparation and their therapeutic uses
WO2002062792A1 (en) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
WO2002080974A1 (en) * 2001-04-04 2002-10-17 Sankyo Company, Limited Novel medicinal use of cytokine production inhibitor
WO2002094267A1 (en) * 2001-05-24 2002-11-28 Sankyo Company, Limited Pharmaceutical composition for prevention or treatment of arthritis
WO2003015781A1 (en) * 2001-08-15 2003-02-27 Sankyo Company, Limited Novel antidiabetic pharmaceutical compositions
WO2004009592A1 (ja) * 2002-07-19 2004-01-29 Sankyo Company, Limited 二環性不飽和３級アミン化合物
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
WO2013049559A1 (en) * 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Pyridine derivatives
JP6299591B2 (ja) 2012-07-03 2018-03-28 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5792778A (en) * 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
EP0863757B1 (en) * 1995-08-10 2003-03-26 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
AU773453B2 (en) 2004-05-27
ES2216826T3 (es) 2004-11-01
TWI259834B (en) 2006-08-11
CN1295069A (zh) 2001-05-16
IL137365A0 (en) 2001-07-24
EP1070711A3 (en) 2001-01-31
TR200002120A3 (tr) 2001-06-21
DK1070711T3 (da) 2004-05-10
CA2314373A1 (en) 2001-01-21
HU0002846D0 (en) 2000-09-28
DE60009804T2 (de) 2005-01-05
NO20003734L (no) 2001-01-22
MXPA00007199A (es) 2003-03-12
HK1033671A1 (en) 2001-09-14
DE60009804D1 (de) 2004-05-19
NO20003734D0 (no) 2000-07-20
EP1070711A2 (en) 2001-01-24
EP1243589A1 (en) 2002-09-25
PT1070711E (pt) 2004-06-30
HK1047587A1 (en) 2003-02-28
ATE264319T1 (de) 2004-04-15
AU4875500A (en) 2001-02-01
AR024904A1 (es) 2002-10-30
KR100776958B1 (ko) 2007-11-27
ID26611A (id) 2001-01-25
NZ505924A (en) 2001-11-30
PL341620A1 (en) 2001-01-29
TR200002120A2 (tr) 2001-06-21
KR20070026708A (ko) 2007-03-08
KR20010049843A (ko) 2001-06-15
HUP0002846A2 (hu) 2002-07-29
CN1294129C (zh) 2007-01-10
EP1070711B1 (en) 2004-04-14

Similar Documents

Publication Publication Date Title
BR0004534A (pt) Composto, composição farmacêutica, agente contendo um composto, e uso de um composto.
BR9806413A (pt) Composto e uso do mesmo
PT1140993E (pt) Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos
BR9908764A (pt) Composto e seus sais farmaceuticamente aceitáveis ou ésteres hidrolisáveis in vivo, uso destes, processo para prepará-los, e, composição farmacêutica
TR199901578T2 (xx) Klaritromisin form 0 kristali
TR199800720T2 (xx) Farnesil transferaz inhibe eden 2-kinolon t�revleri.
BR0207809A (pt) Compostos heteroarila contendo nitrogênio possuindo atividade inibidora contra integrase de hiv
CA2011346A1 (en) 2-(1-piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same
BR0014133A (pt) Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
DE69830504D1 (de) Antithrombotische mitteln
BR0010520A (pt) Novos compostos farmaceuticamente ativos
HUP0004333A2 (hu) Új triazolo [4,5-d] pirimidin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE306261T1 (de) Antithrombosemittel
ATE177420T1 (de) Cyclobutan-derivate als inhibitoren der squalen- synthetase und der protein-farnesyltransferase
BR0208338A (pt) Derivados de piridina
MEP24608A (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
DK1200412T3 (da) Antiproliferative imidazolforbindelser
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
HUP0202469A2 (hu) Sejt adhéziós inhibitor vegyület és ilyet tartalmazó gyógyszerkészítmény
BR9706792A (pt) Derivado de tiazol
BR0112521A (pt) Indolquinazolinonas
DE60001586D1 (de) Diphenyl-piperidin derivate
SE9904129D0 (sv) Novel compounds
BR9712221A (pt) Uso de pelo menos um 1,3-bis(n-lactamil) propano, composto, e, composições farmacêutica e cosmética.
BR0208566A (pt) Derivados de beta-carbolina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.